Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency (SFIDS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00495781 |
Recruitment Status
:
Completed
First Posted
: July 3, 2007
Last Update Posted
: July 3, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Functional Iron Deficiency | Procedure: %-hypo (laboratory parameter, functional iron deficiency) Procedure: CHr (laboratory parameter, functional iron deficiency) Procedure: RET-HE (laboratory parameter, functional iron deficiency) | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 77 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Primary Purpose: | Diagnostic |
Official Title: | Swiss Functional Iron Deficiency Study |
Study Start Date : | October 2004 |
Actual Study Completion Date : | May 2006 |

- Change in Hemoglobin [ Time Frame: 12 months ]
- Costs = erythropoietin/darbepoetin prescribed [ Time Frame: 12 months ]
- Changes in soluble transferrin receptor [ Time Frame: 12 months ]
- Changes in transferrin saturation [ Time Frame: 12 months ]
- changes in ferritin [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- renal anemia, glomerular filtration rate < 10 ml/min
- therapy with either erythropoietin or darbepoetin
- dialysis patients
- therapy with iron
Exclusion Criteria:
- cancer
- autoimmune diseases
- chronic inflammation
- liver disease
- thalassemia, and other causes of anemia (except for renal anemia and iron deficiency anemia)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00495781
Switzerland | |
Spital Zollikerberg | |
Zollikerberg, Zürich, Switzerland, 8125 |
Principal Investigator: | Boris E Schleifenbaum, MD | Viollier Inc. |
ClinicalTrials.gov Identifier: | NCT00495781 History of Changes |
Other Study ID Numbers: |
SFIDS-2004 |
First Posted: | July 3, 2007 Key Record Dates |
Last Update Posted: | July 3, 2007 |
Last Verified: | July 2007 |
Keywords provided by Spital Zollikerberg:
functional iron deficiency renal anemia dialysis erythropoietin darbepoetin |
Additional relevant MeSH terms:
Anemia, Iron-Deficiency Anemia, Hypochromic Anemia Hematologic Diseases Iron Metabolism Disorders Metabolic Diseases |
Iron Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |